Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 12, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Retinitis Pigmentosa

Interventions

DRUG

ZVS203e

ZVS203e is a rAAV-mediated gene editing drug that silences RHO mutant protein expression by CRISPR/Cas9 editing system.

Trial Locations (1)

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors

lead

Peking University Third Hospital

OTHER